Biochemical insights into the role of matrix metalloproteinases in regeneration: Challenges and recent developments

Future Medicinal Chemistry

Volumn 1, Issue 6, 2009, Pages 1095-1111

  Bellayr, Ih ^a,b   Mu, X ^a,c   Li, Y ^a,b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b University of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PD 166793; PGE 7113313; RECOMBINANT INTERLEUKIN 10; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

HEART; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY PARENCHYMA; LIVER; NERVOUS TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; REVIEW; SKELETAL MUSCLE; SKIN; TISSUE REGENERATION; WOUND HEALING;

ANIMALS; CENTRAL NERVOUS SYSTEM; ENZYME ACTIVATION; FEMALE; HEART; HUMANS; KIDNEY; LIVER; MATRIX METALLOPROTEINASES; MUSCLE, SKELETAL; PREGNANCY; PROTEIN PRECURSORS; REGENERATION; SKIN; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77953407314     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.83     Document Type: Review

References (146)

1. Huxley-Jones, J, Clarke TK, Beck C, Toubaris G, Robertson DL, Boot-Handford RP. The evolution of the vertebrate metzincins; insights from Ciona intestinalis and Danio rerio. BMC Evol. Biol. 7, 63 (2007).
2. Gomis-Ruth FX. Structural aspects of the metzincin clan of metalloendopeptidases. Mol. Biotechnol. 24, 157-202 (2003).
3. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221-233 (2007).
4. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ. Matrix metalloproteinases. Br. J. Surg. 84, 160-166 (1997).
5. Somerville RP, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol. 4, 216 (2003).
6. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839 (2003).
7. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596 (2007).
8. Caron NJ, Asselin I, Morel G, Tremblay JP. Increased myogenic potential and fusion of matrilysin-expressing myoblasts transplanted in mice. Cell Transplant 8, 465-476 (1999).
9. Yu F, Kamada H, Niizuma K, Endo H, Chan PH. Induction of MMP-9 expression and endothelial injury by oxidative stress after spinal cord injury. J. Neurotrauma 25, 184-195 (2008).
10. Akhavani MA, Madden L, Buysschaert I, Sivakumar B, Kang N, Paleolog EM. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res. Ther. 11, R64 (2009).
11. Paul S, Sharma AV, Mahapatra PD et al. Role of melatonin in regulating matrix metalloproteinase-9 via tissue inhibitors of metalloproteinase-1 during protection against endometriosis. J. Pineal Res. 44, 439-449 (2008).
12. Vu TD, Yun F, Placido J, Reznik SE. Placental matrix metalloproteinase-1 expression is increased in labor. Reprod. Sci. 15, 420-424 (2008).
13. Choi SJ, Jung KL, Oh SY, Kim JH, Roh CR. Cervicovaginal matrix metalloproteinase-9 and cervical ripening in human term parturition. Eur. J. Obstet. Gynecol. Reprod. Biol. 142, 43-47 (2009).
14. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534-540 (2001).
15. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617-629 (2004).
16. Yang P, Liu Z, Wang H et al. Enhanced activity of very low density lipoprotein receptor II promotes SGC7901 cell proliferation and migration. Life Sci. 84, 402-408 (2009).
17. McCawley LJ, Wright J, LaFleur BJ, Crawford HC, Matrisian LM. Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am. J. Pathol. 173, 1528-1539 (2008).
18. Wang W, Pan H, Murray K, Jefferson BS, Li Y. Matrix metalloproteinase-1 promotes muscle cell migration and differentiation. Am. J. Pathol. 174, 541-549 (2009).
19. Pereira AM, Strasberg-Rieber M, Rieber M. Invasion-associated MMP-2 and MMP-9 are up-regulated intracellularly in concert with apoptosis linked to melanoma cell detachment. Clin. Exp. Metastasis 22, 285-295 (2005).
20. Menon B, Singh M, Singh K. Matrix metalloproteinases mediate b-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes. Am. J. Physiol. Cell Physiol. 289, C168-C176 (2005).
21. Zeng ZZ, Yao H, Staszewski ED et al. a(5) (1) integrin ligand PHSRN induces invasion and a5 mRNA in endothelial cells to stimulate angiogenesis. Transl. Oncol. 2, 8-20 (2009).
22. Shan B, Morris CA, Zhuo Y, Shelby BD, Levy DR, Lasky JA. Activation of proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells. J. Mol. Cell Cardiol. 42, 517-525 (2007).
23. Melendez-Zajgla J, Del Pozo L, Ceballos G, Maldonado V. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol. Cancer 7, 85 (2008).
24. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115, 3719-3727 (2002).
25. Jacobsen J, Visse R, Sorensen HP et al. Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry 47, 537-547 (2008).
26. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal 1, 6 (2008).
27. Hsu JY, Bourguignon LY, Adams CM et al. Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. J. Neurosci. 28, 13467-13477 (2008).
28. Kato T, Kure T, Chang JH et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 508, 187-190 (2001).
29. VanSaun M, Herrera AA, Werle MJ. Structural alterations at the neuromuscular junctions of matrix metalloproteinase 3 null mutant mice. J. Neurocytol. 32, 1129-1142 (2003).
30. Wells JE, Rice TK, Nuttall RK et al. An adverse role for matrix metalloproteinase after spinal cord injury in mice. J. Neurosci. 23, 10107-10115 (2003)
31. Zhou, Z, Apte SS, Soininen R et al. Impaired endochondral ossification and angiogenesis in mice deficient in membranetype matrix metalloproteinase I. Proc. Natl Acad. Sci. USA 97, 4052-4057 (2000).
32. Creemers EE, Davis JN, Parkhurst AM et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am. J. Physiol. Heart Circ. Physiol. 284, H364-H371 (2003).
33. Fedak PW, Smookler DS, Kassiri Z et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110, 2401-2409 (2004).
34. Brockes JP. Amphibian limb regeneration: rebuilding a complex structure. Science 276, 81-87 (1997).
35. Yokoyama H. Initiation of limb regeneration: the critical steps for regenerative capacity. Dev. Growth Differ. 50, 13-22 (2008).
36. Han M, Yang X, Lee J, Allan CH, Muneoka K. Development and regeneration of the neonatal digit tip in mice. Dev. Biol. 315, 125-135 (2008).
37. Vidal P, Dickson MG. Regeneration of the distal phalanx. A case report. J. Hand Surg. [Br.] 18, 230-233 (1993).
38. Alagoz MS, Uysal CA, Kerem M, Sensoz O. Reverse homodigital artery flap coverage for bone and nailbed grafts in fingertip amputations. Ann. Plast. Surg. 56, 279-283 (2006).
39. Shen W, Li Y, Zhu J, Schwendener R, Huard J. Interaction between macrophages, TGF-b1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. J. Cell Physiol. 214, 405-412 (2008).
40. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 40, 1334-1347 (2008).
41. Campbell LJ, Crews CM. Wound epidermis formation and function in urodele amphibian limb regeneration. Cell Mol. Life Sci. 65, 73-79 (2008).
42. Li Y, Foster W, Deasy BM et al. Transforming growth factor-b1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am. J. Pathol. 164, 1007-1019 (2004).
43. Miyazaki K, Uchiyama K, Imokawa Y, Yoshizato K. Cloning and characterization of cDNAs for matrix metalloproteinases of regenerating newt limbs. Proc. Natl Acad. Sci. USA 93, 6819-6824 (1996).
44. Satoh A, Bryant SV, Gardiner DM. Regulation of dermal fibroblast dedifferentiation and redifferentiation during wound healing and limb regeneration in the Axolotl. Dev. Growth Differ. 50, 743-754 (2008).
45. Vinarsky V, Atkinson DL, Stevenson TJ, Keating MT, Odelberg SJ. Normal newt limb regeneration requires matrix metalloproteinase function. Dev. Biol. 279, 86-98 (2005).
46. Yang EV, Gardiner DM, Carlson MR, Nugas CA, Bryant SV. Expression of Mmp-9 and related matrix metalloproteinase genes during axolotl limb regeneration. Dev. Dyn. 216, 2-9 (1999).
47. Crawford K, Stocum DL. Retinoic acid coordinately proximalizes regenerate pattern and blastema differential affinity in axolotl limbs. Development 102, 687-698 (1988).
48. McClure KD, Sustar A, Schubiger G. Three genes control the timing, the site and the size of blastema formation in Drosophila. Dev. Biol. 319, 68-77 (2008).
49. Gourevitch D, Clark L, Chen P, Seitz A, Samulewicz SJ, Heber-Katz E. Matrix metalloproteinase activity correlates with blastema formation in the regenerating MRL mouse ear hole model. Dev. Dyn. 226, 377-387 (2003).
50. Bai S, Thummel R, Godwin AR et al. Matrix metalloproteinase expression and function during fin regeneration in zebrafish: analysis of MT1-MMP, MMP2 and TIMP2. Matrix Biol. 24, 247-260 (2005).
51. Fitzgerald J, Rich C, Burkhardt D, Allen J, Herzka AS, Little CB. Evidence for articular cartilage regeneration in MRL/MpJ mice. Osteoarthritis Cartilage 16, 1319-1326 (2008).
52. Huard J, Li Y, Fu FH. Muscle injuries and repair: current trends in research. J. Bone Joint Surg. Am. 84, 822-832 (2002).
53. Nozaki M, Li Y, Zhu J et al. Improved muscle healing after contusion injury by the inhibitory effect of suramin on myostatin, a negative regulator of muscle growth. Am. J. Sports Med. 36, 2354-2362 (2008).
54. Chan YS, Li Y, Foster W, Fu FH, Huard J. The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury. Am. J. Sports Med. 33, 43-51 (2005).
55. Alexakis C, Partridge T, Bou-Gharios G. Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction. Am. J. Physiol. Cell Physiol. 293, C661-C669 (2007).
56. Sato K, Li Y, Foster W et al. Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosis. Muscle Nerve 28, 365-372 (2003).
57. Foster W, Li Y, Usas A, Somogyi G, Huard J. g-interferon as an antifibrosis agent in skeletal muscle. J. Orthop. Res. 21, 798-804 (2003).
58. Li Y, Li J, Zhu J et al. Decorin gene transfer promotes muscle cell differentiation and muscle regeneration. Mol. Ther. 15, 1616-1622 (2007).
59. Bedair HS, Karthikeyan T, Quintero A, Li Y, Huard J. Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. Am. J. Sports Med. 36, 1548-1554 (2008).
60. Bedair H, Liu TT, Kaar JL et al. Matrix metalloproteinase-1 therapy improves muscle healing. J. Appl. Physiol. 102, 2338-2345 (2007).
61. Kaar JL, Li Y, Blair HC et al. Matrix metalloproteinase-1 treatment of muscle fibrosis. Acta Biomater. 4, 1411-1420 (2008).
62. Nishimura T, Nakamura K, Kishioka Y, Kato-Mori Y, Wakamatsu J, Hattori A. Inhibition of matrix metalloproteinases suppresses the migration of skeletal muscle cells. J. Muscle Res. Cell Motil. 29, 37-44 (2008).
63. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55, 1261-1277 (2003).
64. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23, 47-55 (2005).
65. Lutolf MP, Lauer-Fields JL, Schmoekel HG et al. Synthetic matrix metalloproteinasesensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl Acad. Sci. USA 100, 5413-5418 (2003).
66. Lei Y, Segura T. DNA delivery from matrix metalloproteinase degradable poly(ethylene glycol) hydrogels to mouse cloned mesenchymal stem cells. Biomaterials 30, 254-265 (2009).
67. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578-1580 (1989).
68. Hnia K, Gayraud J, Hugon G et al. l-arginine decreases inflammation and modulates the nuclear factor-kB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 172, 1509-1519 (2008).
69. Bani C, Lagrota-Candido J, Pinheiro DF et al. Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice. Muscle Nerve 37, 583-592 (2008).
70. Zimowska M, Brzoska E, Swierczynska M, Streminska W, Moraczewski J. Distinct patterns of MMP-9 and MMP-2 activity in slow and fast twitch skeletal muscle regeneration in vivo. Int. J. Dev. Biol. 52, 307-314 (2008).
71. Fukushima K, Nakamura A, Ueda H et al. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet. Disord. 8, 54 (2007).
72. Ohtake Y, Tojo H, Seiki M. Multifunctional roles of MT1-MMP in myofiber formation and morphostatic maintenance of skeletal muscle. J. Cell Sci. 119, 3822-3832 (2006).
73. Furochi H, Tamura S, Takeshima K et al. Overexpression of osteoactivin protects skeletal muscle from severe degeneration caused by long-term denervation in mice. J. Med. Invest. 54, 248-254 (2007).
74. Pouw MH, Hosman AJ, van Middendorp JJ, Verbeek MM, Vos PE, van de Meent H. Biomarkers in spinal cord injury. Spinal Cord 47(7), 519-525 (2009).
75. Ruff RL, McKerracher L, Selzer ME. Repair and neurorehabilitation strategies for spinal cord injury. Ann. NY Acad. Sci. 1142, 1-20 (2008).
76. Liu LY, Zheng H, Xiao HL et al. Comparison of blood-nerve barrier disruption and matrix metalloprotease-9 expression in injured central and peripheral nerves in mice. Neurosci. Lett. 434, 155-159 (2008). n Examines how MMP9 expression varied between injuries to the central and peripheral nervous systems.
77. Tabesh H, Amoabediny G, Nik NS et al. The role of biodegradable engineered scaffolds seeded with Schwann cells for spinal cord regeneration. Neurochem. Int. 54, 73-83 (2009).
78. Fleming JC, Norenberg MD, Ramsay DA et al. The cellular inflammatory response in human spinal cords after injury. Brain 129, 3249-3269 (2006).
79. Hsu JY, McKeon R, Goussev S et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J. Neurosci. 26, 9841-9850 (2006).
80. Lehmann HC, Kohne A, Bernal F et al. Matrix metalloproteinase-2 is involved in myelination of dorsal root ganglia neurons. Glia 57, 479-489 (2009).
81. Werner SR, Dotzlaf JE, Smith RC. MMP-28 as a regulator of myelination. BMC Neurosci. 9, 83 (2008).
82. Chattopadhya S, Shubayev VI. MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway. Glia 57(12), 1316-1325 (2009).
83. Yang LJ, Schnaar RL. Axon regeneration inhibitors. Neurol. Res. 30, 1047-1052 (2008).
84. Werner SR, Mescher AL, Neff AW et al. Neural MMP-28 expression precedes myelination during development and peripheral nerve repair. Dev. Dyn. 236, 2852-2864 (2007).
85. Toft-Hansen H, Nuttall RK, Edwards DR, Owens T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J. Immunol. 173, 5209-5218 (2004).
86. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 14, 1189-1197 (2007).
87. Toft-Hansen H, Babcock AA, Millward JM, Owens T. Downregulation of membrane type-matrix metalloproteinases in the inflamed or injured central nervous system. J. Neuroinflammation 4, 24 (2007).
88. Martin P. Wound healing - aiming for perfect skin regeneration. Science 276, 75-81 (1997).
89. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch. Dermatol. Res. 290(Suppl.), S47-S54 (1998).
90. Salo T, Makela M, Kylmaniemi M, Autio-Harmainen H, Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab. Invest. 70, 176-182 (1994).
91. Saarialho-Kere UK, Chang ES, Welgus HG, Parks WC. Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J. Clin. Invest. 90, 1952-1957 (1992).
92. Petersen MJ, Woodley DT, Stricklin GP, O'Keefe EJ. Enhanced synthesis of collagenase by human keratinocytes cultured on type I or type IV collagen. J. Invest. Dermatol. 94, 341-346 (1990).
93. Saarialho-Kere UK, Pentland AP, Birkedal-Hansen H, Parks WC, Welgus HG. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J. Clin. Invest. 94, 79-88 (1994).
94. Vaalamo M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. Hum. Pathol. 30, 795-802 (1999).
95. Toriseva M, Kahari VM. Proteinases in cutaneous wound healing. Cell Mol. Life Sci. 66, 203-224 (2009).
96. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Repair Regen. 4, 321-325 (1996).
97. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J. Invest. Dermatol. 101, 64-68 (1993).
98. Vaalamo M, Kariniemi AL, Shapiro SD, Saarialho-Kere U. Enhanced expression of human metalloelastase (MMP-12) in cutaneous granulomas and macrophage migration. J. Invest. Dermatol. 112, 499-505 (1999).
99. Wilgus TA. Regenerative healing in fetal skin: a review of the literature. Ostomy. Wound Manage. 53, 16-33 (2007).
100. Dang CM, Beanes SR, Lee H, Zhang X, Soo C, Ting K. Scarless fetal wounds are associated with an increased matrix metalloproteinase-to-tissue-derived inhibitor of metalloproteinase ratio. Plast. Reconstr. Surg. 111, 2273-2285 (2003).
101. Satoh A, Graham GM, Bryant SV, Gardiner DM. Neurotrophic regulation of epidermal dedifferentiation during wound healing and limb regeneration in the axolotl (Ambystoma mexicanum). Dev. Biol. 319, 321-335 (2008).
102. Manuel JA, Gawronska-Kozak B. Matrix metalloproteinase 9 (MMP-9) is upregulated during scarless wound healing in athymic nude mice. Matrix Biol. 25, 505-514 (2006).
103. Chen W, Fu X, Ge S, Sun T, Sheng Z. Differential expression of matrix metalloproteinases and tissue-derived inhibitors of metalloproteinase in fetal and adult skins. Int. J. Biochem. Cell Biol. 39, 997-1005 (2007).
104. Xie J, Bian H, Qi S et al. Effects of basic fibroblast growth factor on the expression of extracellular matrix and matrix metalloproteinase-1 in wound healing. Clin. Exp. Dermatol. 33, 176-182 (2008).
105. Kuramochi D, Unoki H, Bujo H et al. Matrix metalloproteinase 2 improves the transplanted adipocyte survival in mice. Eur. J. Clin. Invest. 38, 752-759 (2008).
106. Dasu MR, Hawkins HK, Barrow RE, Xue H, Herndon DN. Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. J. Pathol. 202, 476-485 (2004).
107. Philips N, Keller T, Gonzalez S. TGF b-like regulation of matrix metalloproteinases by anti-transforming growth factor-b, and anti-transforming growth factor-b1 antibodies in dermal fibroblasts: implications for wound healing. Wound Repair Regen. 12, 53-59 (2004).
108. Yao XM, Zhao J, Li Y. Effects of bicyclol on liver regeneration after partial hepatectomy in rats. Dig. Dis. Sci. 54, 774-781 (2009).
109. Chen MF, Hwang TL, Hung CF. Human liver regeneration after major hepatectomy. A study of liver volume by computed tomography. Ann. Surg. 213, 227-229 (1991).
110. Iimuro Y, Nishio T, Morimoto T et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124, 445-458 (2003).
111. Svegliati-Baroni G, D'Ambrosio L, Ferretti G et al. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 27, 720-726 (1998).
112. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem. J. 411, 1-18 (2008).
113. Han YP, Yan C, Zhou L, Qin L, Tsukamoto H. A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the threedimensional extracellular matrix. J. Biol. Chem. 282, 12928-12939 (2007).
114. Kirimlioglu H, Kirimlioglu V, Yilmaz S. Expression of matrix metalloproteinases 2 and 9 in donor liver, cirrhotic liver, and acute rejection after human liver transplantation. Transplant Proc. 40, 3574-3577 (2008).
115. Pham Van T, Couchie D, Martin-Garcia N, Laperche Y, Zafrani ES, Mavier P. Expression of matrix metalloproteinase-2 and -9 and of tissue inhibitor of matrix metalloproteinase-1 in liver regeneration from oval cells in rat. Matrix Biol. 27, 674-681 (2008).
116. Zhou X, Hovell CJ, Pawley S et al. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int. 24, 492-501 (2004).
117. Olle EW, Ren X, McClintock SD et al. Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice. Hepatology 44, 540-549 (2006).
118. Alwayn IP, Verbesey JE, Kim S et al. A critical role for matrix metalloproteinases in liver regeneration. J. Surg. Res. 145, 192-198 (2008).
119. Preaux AM, Mallat A, Nhieu JT, D'Ortho MP, Hembry RM, Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 30, 944-950 (1999).
120. Roderfeld M, Weiskirchen R, Wagner S et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J. 20, 444-454 (2006).
121. Hu YB, Li DG, Lu HM. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J. Gene Med. 9, 217-229 (2007).
122. Mohammed FF, Pennington CJ, Kassiri Z et al. Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology 41, 857-867 (2005).
123. Mohammed FF, Smookler DS, Taylor SE et al. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat. Genet. 36, 969-977 (2004).
124. Krishnamurthy P, Peterson JT, Subramanian V, Singh M, Singh K. Inhibition of matrix metalloproteinases improves left ventricular function in mice lacking osteopontin after myocardial infarction. Mol. Cell Biochem. 322, 53-62 (2009).
125. Tessone A, Feinberg MS, Barbash IM et al. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc. Drugs Ther. 19, 383-390 (2005).
126. Cleutjens JP, Creemers EE. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction. J. Card. Fail. 8, S344-S338 (2002).
127. Gaertner R, Jacob MP, Prunier F, Angles-Cano E, Mercadier JJ, Michel JB. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat. J. Mol. Cell Cardiol. 38, 193-204 (2005).
128. Parfyonova YV, Plekhanova OS, Tkachuk VA. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc.) 67, 119-134 (2002).
129. Lu L, Zhang JQ, Ramires FJ, Sun Y. Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissue. Biochem. Biophys. Res. Commun. 320, 907-913 (2004).
130. Mukherjee R, Bruce JA, McClister DM Jr, Allen CM, Sweterlitsch SE, Saul JP. Time-dependent changes in myocardial structure following discrete injury in mice deficient of matrix metalloproteinase-3. J. Mol. Cell Cardiol. 39, 259-268 (2005).
131. van Amerongen MJ, Harmsen MC, Petersen AH, Kors G, van Luyn MJ. The enzymatic degradation of scaffolds and their replacement by vascularized extracellular matrix in the murine myocardium. Biomaterials 27, 2247-2257 (2006).
132. Moe GW, Laurent G, Doumanovskaia L, Konig A, Hu X, Dorian P. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure. J. Card. Fail. 14, 768-776 (2008).
133. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y. Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J. Pharmacol. Sci. 108, 487-494 (2008).
134. Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ. Res. 104, E9-E18 (2009).
135. Ogawa M, Suzuki J, Takayama K, Isobe M. Matrix metalloproteinase suppression induced by clarithromycin in murine cardiac allografts. Transplant Proc. 41, 395-397 (2009).
136. Roten L, Nemoto S, Simsic J et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J. Mol. Cell Cardiol. 32, 109-120 (2000).
137. Nony PA, Schnellmann RG. Mechanisms of renal cell repair and regeneration after acute renal failure. J. Pharmacol. Exp. Ther. 304, 905-912 (2003).
138. Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 35, 1-10 (2009).
139. Munkert A, Helmchen U, Kemper MJ, Bubenheim M, Stahl RA, Harendza S. Characterization of the transcriptional regulation of the human MT1-MMP gene and association of risk reduction for focal-segmental glomerulosclerosis with two functional promoter SNPs. Nephrol. Dial. Transplant 24, 735-742 (2009).
140. Liu WH, Tang NN, Zhang QD. Could mycophenolate mofetil combined with benazapril delay tubulointerstitial fibrosis in 5/6 nephrectomized rats? Chin. Med. J. (Engl.) 122, 199-204 (2009).
141. Chromek M, Tullus K, O Hertting et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatr. Res. 53, 698-705 (2003).
142. Yao XM, Ye SD, Chen Y et al. Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression. Diabetes Obes. Metab. 11, 519-522 (2009).
143. Castro MM, Rizzi E, Rodrigues GJ et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic. Biol. Med. 46, 1298-1307 (2009).
144. Pulukuri SM, Rao JS. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int. J. Oncol. 32, 757-765 (2008).
145. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239 (2006).
146. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc. Am. Thorac. Soc. 3, 383-388 (2006).